Dr. Tim Rodell, Chief Executive Officer, Aethlon Medical brings us up to speed on the work at Aethlon in developing immunotherapeutic technologies using their Hemopurifier to clear a virus as well as exosomes in patients with cancer as blood flows through the nanofibers of the Hemopurifier cartridge. With more recent understanding of the role of exosomes in the spread of cancer, Aethlon is exploring the advantage of adding treatment with Hemopurifier to make more patients respond to Keytruda. With an Investigational Device Exemption (IDE) from the FDA, Aethlon is opening clinical trials on treating COVID-19 with Hemopurifier to remove the SARS-CoV-2 COVID virus from the circulation.
@aethlon_medical #immunotherapy #cancer #exosomes #Infectiousdiseases #COVID19
AethlonMedical.com
Download the transcript here.
Empowered Patient Podcast